Search for drugs:
Typing the drug name to query
DEXLANSOPRAZOLE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At a dose five times the maximum recommended dose, dexlansoprazole does not prolong the QT interval to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
2
24090
Other ADRs
12084
38369503
Odds Ratio = 0.264
Drug Property Information
ATC Code(s):
- A02BC06 - dexlansoprazole
- A02BC - Proton pump inhibitors
- A02B - DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
- A02 - DRUGS FOR ACID RELATED DISORDERS
- A - ALIMENTARY TRACT AND METABOLISM
Active Ingredient:dexlansoprazole
Active Ingredient UNII:UYE4T5I70X
Drugbank ID:DB05351
PubChem Compound:9578005
CTD ID:D064748
PharmGKB:PA166110257
CAS Number:138530-94-6
Dosage Form(s):capsule, delayed release
Route(s) Of Administrator:oral
Daily Dose:
- 30.0 mg/day A02BC06
Chemical Structure: 
SMILE Code:
CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1
CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.